Euromarkets

Ebb & Flow Focus

OXFORD - Just over five years ago, Europe's entrepreneurial bioscience companies had very little choice if they wanted to access public equity. It was either a case of cranking up the air miles and go for an IPO on NASDAQ, or wait until the company could meet the stringent requirements associated with admission to Europe's senior bourses; which would entail a very long wait...